Sign In
Buy REGN
$628.73
+9.78 (+1.58%)
At Close: Jun 04, 2026
SAN DIEGO , Jan. 10, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities between N
Why Regeneron (REGN) is Poised to Beat Earnings Estimates Again
01:15pm, Friday, 10'th Jan 2025
Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
NEW YORK, NY / ACCESSWIRE / January 10, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal se
NEW YORK, NY / ACCESSWIRE / January 10, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal se
The Schall Law Firm Urges Shareholders With Losses To Join A Securities Fraud Case Against Regeneron Pharmaceuticals, Inc.
11:15am, Friday, 10'th Jan 2025
LOS ANGELES, CA / ACCESSWIRE / January 10, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc
Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN) Seeking Recovery for Investors - Contact Levi & Korsinsky
09:00am, Friday, 10'th Jan 2025
NEW YORK, NY / ACCESSWIRE / January 10, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal se
NEW YORK CITY, NY / ACCESSWIRE / January 9, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Regeneron
SAN FRANCISCO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) faces a securities fraud class action after shares of the company plunged $84.59 on Oct. 31, 2024, wipin
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
07:30pm, Wednesday, 08'th Jan 2025
LOS ANGELES--(BUSINESS WIRE)--REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm.
The Schall Law Firm Urges Shareholders With Losses To Join A Securities Fraud Case Against Regeneron Pharmaceuticals, Inc.
07:30pm, Wednesday, 08'th Jan 2025
LOS ANGELES, CA / ACCESSWIRE / January 8, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc.
Stockholder Notice: Robbins LLP Informs Stockholders of the Regeneron Pharmaceuticals, Inc. Class Action Lawsuit
06:38pm, Wednesday, 08'th Jan 2025
SAN DIEGO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Regeneron Pharmaceu
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Regeneron Pharmaceuticals, Inc. (REGN)
06:11pm, Wednesday, 08'th Jan 2025
NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of N
SAN DIEGO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities between November 2, 20
NEW YORK CITY, NY / ACCESSWIRE / January 8, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Regeneron
NEW YORK, NY / ACCESSWIRE / January 8, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Regeneron Ther
